Taking the Lead Presidents Address ASN Kidney Week 2020 Reimagined - - PowerPoint PPT Presentation

President’s Address ASN Kidney Week 2020 Reimagined Anupam Agarwal, MD, FASN

NEPHROLOGY

Taking the Lead

Jon B. Klein, MD, PHD, FASN

Co-Chair, ASN Kidney Week Education Committee

Linda F. Fried, MD, MPH, FASN

Co-Chair, ASN Kidney Week Education Committee

Jonathan Himmelfarb, MD, FASN John Sedor, MD, FASN Raymond C. Harris, MD, FASN Eleanor D. Lederer, MD, FASN Prabir Roy-Chaudhury, MD, PhD FASN Mark D. Okusa, MD, FASN Crystal A. Gadegbeku, MD, FASN David H. Ellison, MD, FASN Keisha L. Gibson, MD, FASN Barbara T. Murphy, MB BAO, BCh, FRCPI Susan E. Quaggin, MD, FASN Mark E. Rosenberg, MD, FASN Tod Ibrahim Executive Vice President

UAB Division of Nephrology

K.S. Chugh Karl A. Nath

• C. Craig Tisher

Harry S. Nick

https://aakp.org/decade-of-the-kidney/

Taking the Lead

Slide 11

Building our Workforce Advancing Diversity, Inclusion and Equity Expanding Innovation and Collaboration

Why are we having difficulty attracting others into our specialty?

1988 ASN Presidential Address

Slide 12

Thomas F. Ferris, MD

Figure 1. Daily parameters, average week-by-week, 1/1/19 - 6/9/20. Daily hospital admissions decreased during the COVID-19 period (A). Concurrently, the absolutely number of daily consults and daily CRRT treatments increased. Shaded area represents the months of March, April, May, which in 2020 were the early, surge, and late periods in NY. From: Hirsch et al., Clin Neph, doi 10.5414/CN110312

Saakshi Thukral - KDSAP

AAMC from 2017 AMA Masterfile

Percentage of Active Physicians Who Are IMGs, by Specialty

What Improvements is ASN pushing for?

Policies should continue to identify physicians as important for national security; Prioritize processing for physicians and medical residents; Expedite adjudications and extend visas and other protected status for physicians and medical residents through the COVID-19 national emergency; Continue and expand the H-1B premium processing option; Open visa processing at embassies and consulates worldwide for physicians and medical residents; Allow physicians and medical residents

• n J-1 and H-1B visas to be

redeployed as needed to respond to the COVID-19 pandemic.

Medscape

How Much Do Nephrologists Earn?

Compensation Nephrology vs Other Specialties

Employed physicians reported salary, bonus and profit-sharing contributions

Task Force on Academic Nephrologists Compensation and Productivity

Use transplant nephrology as a model to:

• Recommend approaches to help address specific areas of most

concern to US nephrologists relative to physician productivity and compensation.

• Generate robust and generalizable data on compensation that will

help inform and improve current and future compensation models:

• Evaluate the downstream revenue/return on investment from

transplant nephrologist led activities.

• Identify the compensation areas ASN and other stakeholders could

most likely address:

Cardiology Nephrology

Cardiovascular Disease General Nephrology, including:

• Cardiorenal disease
• Hypertension
• Diabetic kidney disease
• Glomerular diseases, such as polycystic kidney disease

Clinical cardiac electrophysiology Dialysis Care (including in-center and home modalities) Interventional cardiology Interventional Nephrology Advanced heart failure and transplant cardiology Transplant Nephrology Adult congenital heart disease Critical Care Nephrology and Acute Kidney Injury Onconephrology

Cardiology as a Potential Model for Sub-specialization in Nephrology

ASN Survey to Capture Data Across the Career Trajectory

ASN will extend the fellows’ survey data (surveys begun in 2014) to capture the full trajectory from undifferentiated student through retirement, and to help address the workforce crisis. Identify local, regional, national trends in employment (geographic, practice type, race/ethnicity/sex). Capture the effects of structural racism in nephrology. Analyze differences in expectations vs employment over time, including geography, career focus and compensation. Apply more granular data to begin to measure debt and impact of loan mitigation. Build detailed data to reflect potential areas

• f sub-specialization within nephrology.

Determine regional differences that may impact rollout of home dialysis and telehealth initiatives.

Taking the Lead

Slide 24

Advancing Diversity, Inclusion, and Equity

A diverse mix of voices leads to better discussions, decisions, and outcomes for everyone.

Sundar Pichai CEO, Google, Inc. and Alphabet, Inc

Diversity is being invited to the party; inclusion is being asked to dance.

Verna Myers Founder and president of Verna Myers Consulting Group

ASN Council 2020

ASN Call to Action

The ASN Diversity and Inclusion Committee established several groups that work across ASN to dismantle systemic racism. The committee will report progress and challenges regularly to the ASN Council.

Work Group/Category ASN Alliance Entities 1. Address equity in private practice

• ASN Policy and Advocacy Committee
• ASN Quality Committee
• AKI!Now Steering Committee
• COVID-19 Response Team
• Diabetic Kidney Disease-Collaborative (DKD-C) Task

Force

• Nephrologists Transforming Dialysis Safety (NTDS)

Project Committee 2. Evaluate, redesign, and implement training for trainees and program directors

• ASN Workforce and Training Committee

3. Examine career advancement

• ASN Career Advancement Committee

4. Engage with NIH and NIDDK

• ASN Policy and Advocacy Committee
• KHI Board of Directors
• KidneyX Steering Committee

5. Evaluate the (ASN) awards selection committee and council nominations

• ASN Award Selection Committee
• ASN Nominating Committee

30% 45%

Proportion of Women: US Nephrologists and Kidney Week 2020 Faculty

Nephrologists KW 2020 Faculty

ASN Loan Mitigation Task Force

ASN Loan Mitigation Pilot Program Task Force Charge

The ASN Loan Mitigation Pilot Program Task Force is charged with providing advice and guidance to help shape the ASN loan mitigation pilot program, including: (1) selecting the best avenues for reaching potential applicants underrepresented in medicine; (2) determining a simple and effective application and review processes that will allow volunteers to make informed choices about recipients; and (3) developing metrics of program success.

Kalani L. Raphael, MD, MS, FASN Javier A. Neyra, MD, MS, FASN Andrew Kowaiski, MD, MPH Nimrit Goraya, MD, FASN Crystal A. Gadegbeku, MD, FASN Council Liaison Nwamaka D. Eneanya, MD, MPH, FASH Chair

Going Beyond the Statement:

Dismantling Systemic Racism in Nephrology

This discussion will center on topics relative to systemic racism in nephrology, science, and medicine; the panel will address the topics suggested most often by those who register for this webinar. ASN is developing a number of initiatives addressing systemic racism in nephrology and recognizes that no single effort represents an all-inclusive solution to complex challenges. We hope that by engaging the community and incorporating many perspectives during this key discussion, we will add to actionable items that ASN can support in order to better serve kidney professionals, advance excellence in our profession, and improve care of those with kidney diseases.

• J. Kevin Tucker, MD

Will Ross, MD, MPH, FASN Dana Mitchell, MD, FACP, FASN Vanessa Grubbs, MD, MPH Keisha L. Gibson, MD, MPH, FASN Anupam Agarwal, MD, FASN

Moderators Panelists

Taking the Lead

Slide 33

Expanding Innovation and Collaboration

HHS and ASN Aw ard $3 Million to Winners of Redesign Dialysis Phase 2

Redesign Dialysis Phase 2 Winners

The following submissions were selected as winners of the Redesign Dialysis Phase 2 prize competition:

• A Bioresorbable Shape Memory Polymer Wrap to Improve Maturation and

Patency of Dialysis Access Sites, Timothy Boire, PhD

• A Novel Device to Prevent Infection Due to Touch Contamination in Peritoneal

Dialysis, Sarah Lee

• A Pro-Regenerative Vascular Access Graft: Surmounting Challenges Inhibiting

Progress, Buddy D. Ratner, PhD

• Intracorporeal Hemodialysis System, Shuvo Roy, PhD
• Developing Self-Renewable "Living" Endothelium Vascular Grafts for

Hemodialysis, Aijun Wang, PhD

• Nitric Oxide-Eluting, Disposable Hemodialysis Catheter Cap to Prevent Infection

and Thrombosis, Alexander Yevzlin, MD

Vincent Garvey, winner of the Affordable Dialysis Prize

THE AFFORDABLE DIALYSIS PRIZE

World’s first low cost dialysis unveiled.

It’s an invention that could save millions of lives each year and transform the way kidney disease is treated around the world.

Courtesy of Dr. Chris Ketchum, Deputy Director, KUH, NIDDK

Quantity and Reporting Quality

• f Kidney Research

Kyriakos et al., JASN, 2019, 30 (1) 13-22; DOI: https://doi.org/10.1681/ASN.2018050515

National Kidney Foundation - American Society of Nephrology Task Force

Reassessing the inclusion of race in diagnosing kidney diseases Issuing initial recommendations in 2020

• Cynthia Delgado, MD, FASN, Cochair
• Neil R. Powe, MD, FASN, Cochair
• Mukta Baweja, MD
• Nilka Rios Burrows, MPH, MT
• Deidra C. Crews, MD, FASN
• Nwamaka D. Eneanya, MD , MPH, FASN
• Crystal A. Gadegbeku, MD, FASN
• Lesley Inker, MD
• Mallika L. Mendu, MD, MBA
• W. Greg Miller, PhD
• Marva M. Moxey-Mims, MD, FASN
• Glenda V. Roberts
• Wendy L. St. Peter, PharmD, FASN
• Curtis Warfield, MS

18-510 Research Coordination Networks in Undergraduate Biology Education National Science Foundation 20-559 Historically Black Colleges and Universities – Undergraduate Program National Science Foundation W81XWH-20-KCRP-CRNDA DoD Kidney Cancer, Clinical Research Nurse Development Award Department of Defense

• Dept. of the Army -- USAMRAA

18-330 Investigator-Initiated Clinical Trials Targeting Diseases within the Mission of NIDDK (R01-Clinical Trial Required) Department of Health and Human Services National Institutes of Health PAR-19-030 NIDDK Education Program Grants (R25 Clinical Trial Not Allowed) Department of Health and Human Services National Institutes of Health RFA-DK-20-021 Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional) Department of Health and Human Services National Institutes of Health CDC-RFA-DP21-2107 Supporting and Improving the Surveillance System for Chronic Kidney Disease in the United States Department of Health and Human Services National Institutes of Health

The Hidden Epidemic

More than 850 million people suffer from kidney diseases

Underestimated Problem Most people are not aware of their impaired kidney function. In general, kidney diseases are “silent” with no apparent early

• symptoms. According to the World Health Organization,

kidney diseases are a leading cause of death. 850 Million People More than 850 million people worldwide have some form of kidney disease, which is roughly double the number of people who live with diabetes (422 million) and 20 times more than the prevalence of cancer worldwide (42 million) or people living with AIDS/HIV (36.7 million). Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI) The prevalence of CKD worldwide is 10.4% among men and 11.8% among women. AKI, experienced by 13.3 million people each year, may resolve or lead to CKD or kidney failure in the future. Insufficient Treatment Between 5.3 and 10.5 million people require dialysis or transplantation, although many more do not receive these treatments due to lack of resources of financial barriers. Financial Burden Treating people with kidney diseases and kidney failure impose of heavy financial burden or healthcare budgets, as the annual cost per patient for hemodialysis are, for example, US $88,195 in the USA, up to US $58,812 in Germany, US $83,616 in Belgium or US $70,928 in France.

1 2 3 4 5

Joint Project of:

Implement systems that value and advance our specialty and our contributions to individual patients and to public health.

Dismantle systemic racism in nephrology.

Build a diverse and overflowing pipeline of students and trainees eager to cure kidney diseases.

Overcome the barriers social determinants of health impose on kidney care.

Secure the funding that will spur research, discovery, and innovation as well as improve global health.

We Must Take the Lead